Imperial College London
Alternate

Dr Elizabeth Want

Faculty of Medicine, Department of Metabolism, Digestion and Reproduction

Senior Lecturer
 
 
 
//

Contact

 

+44 (0)20 7594 3023e.want

 
 
//

Location

 

E315CBurlington DanesHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Sigurdsson:2023:10.1186/s12883-023-03081-1,
author = {Sigurdsson, HP and Hunter, H and Alcock, L and Wilson, R and Pienaar, I and Want, E and Baker, MR and Taylor, J-P and Rochester, L and Yarnall, AJ},
doi = {10.1186/s12883-023-03081-1},
journal = {BMC Neurology},
pages = {1--11},
title = {Safety and tolerability of adjunct non-invasive vagus nerve stimulation in people with parkinson's: a study protocol},
url = {http://dx.doi.org/10.1186/s12883-023-03081-1},
volume = {23},
year = {2023}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Parkinson's disease (PD) is the fastest growing neurological condition worldwide. Recent theories suggest that symptoms of PD may arise due to spread of Lewy-body pathology where the process begins in the gut and propagate transynaptically via the vagus nerve to the central nervous system. In PD, gait impairments are common motor manifestations that are progressive and can appear early in the disease course. As therapies to mitigate gait impairments are limited, novel interventions targeting these and their consequences, i.e., reducing the risk of falls, are urgently needed. Non-invasive vagus nerve stimulation (nVNS) is a neuromodulation technique targeting the vagus nerve. We recently showed in a small pilot trial that a single dose of nVNS improved (decreased) discrete gait variability characteristics in those receiving active stimulation relative to those receiving sham stimulation. Further multi-dose, multi-session studies are needed to assess the safety and tolerability of the stimulation and if improvement in gait is sustained over time. DESIGN: This will be an investigator-initiated, single-site, proof-of-concept, double-blind sham-controlled randomised pilot trial in 40 people with PD. Participants will be randomly assigned on a 1:1 ratio to receive either active or sham transcutaneous cervical VNS. All participants will undergo comprehensive cognitive, autonomic and gait assessments during three sessions over 24 weeks, in addition to remote monitoring of ambulatory activity and falls, and exploratory analyses of cholinergic peripheral plasma markers. The primary outcome measure is the safety and tolerability of multi-dose nVNS in PD. Secondary outcomes include improvements in gait, cognition and autonomic function that will be summarised using descriptive statistics. DISCUSSION: This study will report on the proportion of eligible and enrolled patients, rates of eligibility and reasons for ineligibility. Adverse events will be recorde
AU  - Sigurdsson,HP
AU  - Hunter,H
AU  - Alcock,L
AU  - Wilson,R
AU  - Pienaar,I
AU  - Want,E
AU  - Baker,MR
AU  - Taylor,J-P
AU  - Rochester,L
AU  - Yarnall,AJ
DO  - 10.1186/s12883-023-03081-1
EP  - 11
PY  - 2023///
SN  - 1471-2377
SP  - 1
TI  - Safety and tolerability of adjunct non-invasive vagus nerve stimulation in people with parkinson's: a study protocol
T2  - BMC Neurology
UR  - http://dx.doi.org/10.1186/s12883-023-03081-1
UR  - https://www.ncbi.nlm.nih.gov/pubmed/36737716
UR  - https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-023-03081-1
UR  - http://hdl.handle.net/10044/1/102813
VL  - 23
ER  -
Download